10-Q: Lifeward Ltd. Reports Q1 2025 Results, Navigates Financial Challenges

Lifeward Ltd. reports a decrease in revenue for Q1 2025, alongside ongoing efforts to manage financial stability and expand market reach.

Summary

• Lifeward Ltd. reported a net loss of $4.8 million for the quarter ended March 31, 2025.
• Revenue decreased slightly to $5.0 million compared to $5.3 million in the same period last year.
• The company's cash and cash equivalents totaled $5.7 million as of March 31, 2025.
• Lifeward is actively pursuing various strategies to improve its financial position, including cost reductions and revenue growth initiatives.
• The company is expanding its product offerings and market reach through partnerships and acquisitions.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on obtaining necessary financing to meet its obligations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as the launch of ReWalk 7 and new partnerships, the financial results indicate ongoing challenges and concerns about the company's ability to continue as a going concern. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• Gross profit increased to $2.1 million, or 42.2% of revenue, for the three months ended March 31, 2025, compared to $1.4 million, or 26.4% of revenue, for the three months ended March 31, 2024.
• Operating expenses decreased by $0.9 million, or 11.7%, year-over-year.
• The company launched the ReWalk 7, the newest generation of personal exoskeleton, in the U.S. market following FDA clearance in March 2025.
• Lifeward established a new partnership with CorLife for exclusive distribution of the ReWalk Personal Exoskeleton to individuals with workers compensation claims.
• The company finalized an agreement with BARMER in Germany to streamline access to ReWalk exoskeletons for eligible beneficiaries, adding 8.5 million covered lives in Germany.

Negatives

• Lifeward Ltd. reported a net loss of $4.8 million for Q1 2025.
• Revenue decreased slightly to $5.0 million compared to $5.3 million in the same period last year.
• The company's cash and cash equivalents totaled $5.7 million as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's cash position is not sufficient to fund planned operations for at least a year.
• The company's ability to continue as a going concern is dependent on obtaining necessary financing.
• The company is subject to limitations under Form S-3 rules, which constrain its ability to secure capital.
• The company relies on foreign third-party manufacturers and parts suppliers, including those in China, Taiwan and Israel, and is subject to tariffs.
• The company may be materially adversely affected by the imposition of tariffs and other trade barriers and retaliatory countermeasures implemented by the United States and other governments.

Future Outlook

Lifeward expects future growth to be driven by sales of the ReWalk Personal Exoskeleton, AlterG Anti-Gravity system, and MyoCycle device. The company intends to focus research and development resources on supporting current products and making design enhancements to reduce material costs. The company plans to file a new shelf registration statement on Form S-3 to replace the expiring 2022 Shelf Registration Statement.

Management Comments

• The company is working to expand coverage beyond Medicare to the commercial health insurance segment.
• The company expects the partnership with CorLife will achieve greater growth and penetration into the workers compensation market for exoskeletons.
• The company expects the expanded partnership with MYOLYN to broaden Lifewards distribution rights of the MyoCycle FES Cycling Therapy System to include referral sales for home use applications, the largest market segment for functional electrical stimulation (FES) cycles.

Industry Context

Lifeward's focus on expanding reimbursement coverage for its ReWalk Personal Exoskeleton aligns with the broader industry trend of seeking wider adoption of exoskeleton technologies through third-party payor agreements. The partnership with CorLife and the agreement with BARMER are strategic moves to penetrate specific market segments and streamline access to the company's products.

Comparison to Industry Standards

• Comparing Lifeward's performance to companies like Ekso Bionics and Myomo, which also operate in the exoskeleton and rehabilitation robotics space, reveals a similar focus on securing reimbursement and expanding market reach.
• Ekso Bionics, for example, has also been actively pursuing Medicare and commercial insurance coverage for its exoskeleton devices.
• Myomo focuses on upper-limb exoskeletons and has seen success in securing contracts with the VHA.
• Lifeward's revenue of $5.0 million for Q1 2025 is within the range of quarterly revenues reported by these comparable companies, but the company's net loss highlights the ongoing challenges in achieving profitability in this sector.
• The company's gross profit margin of 42.2% is competitive with industry standards, indicating efficient cost management in production and service delivery.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial challenges and dependence on future financing.
• Employees may be affected by cost reduction measures and potential business disruptions.
• Customers and patients can benefit from new product launches and expanded market access, but may also face risks related to the company's financial stability.
• Suppliers and creditors may be impacted by the company's ability to meet its obligations.

Next Steps

• The company plans to file a new shelf registration statement on Form S-3 to replace the expiring 2022 Shelf Registration Statement.
• The company intends to focus research and development resources on supporting current products and making design enhancements to reduce material costs.
• The company will continue to pursue various paths of reimbursement and support fundraising efforts by institutions and clinics.

Key Dates

Keywords

Lifeward, ReWalk, AlterG, Exoskeleton, Financial Results, Q1 2025, Revenue, Net Loss, Warrants, Equity Raise, Going Concern, Medicare, Reimbursement, Partnership, CorLife, BARMER